2024
DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance
Conway K, Edmiston S, Vondras A, Reiner A, Corcoran D, Shen R, Parrish E, Hao H, Lin L, Kenney J, Ilelaboye G, Kostrzewa C, Kuan P, Busam K, Lezcano C, Lee T, Hernando E, Googe P, Ollila D, Moschos S, Gorlov I, Amos C, Ernstoff M, Cust A, Wilmott J, Scolyer R, Mann G, Vergara I, Ko J, Rees J, Yan S, Nagore E, Bosenberg M, Rothberg B, Osman I, Lee J, Saenger Y, Bogner P, Thompson C, Gerstenblith M, Holmen S, Funchain P, Brunsgaard E, Depcik-Smith N, Luo L, Boyce T, Orlow I, Begg C, Berwick M, Thomas N, Berwick M, Luo L, Boyce T, Reynolds A, Wiggins C, Thomas N, Conway K, Edmiston S, Ollila D, Hao H, Parrish E, Googe P, Moschos S, Corcoran D, Vondras A, Tsai Y, Lin L, Shen R, Begg C, Arora A, Seshan V, Reiner A, Kostrzewa C, Busam K, Orlow I, Lezcano C, Kenney J, Sadeghi K, O'Connell K, Ilelaboye G, Parmar H, Leong S, Corrales S, Scolyer R, Cust A, Wilmott J, Mann G, Shang P, Burke H, Ferguson P, Jakrot V, Lee T, Hernando E, Osman I, Hanniford D, Argibay D, Moran U, Heguy A, Ramaswami S, Amos C, Gorlov I, Zhu D, Ernstoff M, Bogner P, Lee J, Rees J, Yan S, Gerstenblith M, Thompson C, Ko J, Funchain P, Ngo P, Bosenberg M, Gould Rothberg B, Panse G, Saenger Y, Fullerton B, Holmen S, Colman H, Brunsgaard E, Wada D, Nagore E, Manrique-Silva E, Requena C, Traves V, Millan-Esteban D, Rainka M. DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance. JCO Precision Oncology 2024, 8: e2400375. PMID: 39509669, DOI: 10.1200/po-24-00375.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerCpG island methylator phenotypePrimary melanomaBreslow thicknessMethylation classClinicopathological characteristicsN stageRisk of melanoma-related deathLow methylationStage IIRetrospective case-control studyCutaneous primary melanomaHigher AJCC stagePrimary cutaneous melanomaHigher N stageMelanoma-related deathDNA methylation classDied of melanomaMitotic indexCase-control studyIII patientsClinicopathological factorsCpG island hypermethylationPrognostic significanceAJCC stage
2023
Oncology hospitalist impact on hospice utilization
Prsic E, Morris J, Adelson K, Parker N, Gombos E, Kottarathara M, Novosel M, Castillo L, Rothberg BE. Oncology hospitalist impact on hospice utilization. Cancer 2023, 129: 3797-3804. PMID: 37706601, DOI: 10.1002/cncr.35008.Peer-Reviewed Original ResearchConceptsMedical oncology serviceOncology servicesEnd of lifeAdvanced cancerInpatient hospiceHospice utilizationHigher total health care costsTotal health care costsComfort-focused careInpatient oncology serviceSmilow Cancer HospitalAdjusted odds ratioLength of staySolid tumor malignanciesLong-term survivalMultivariable linear regressionHealth care costsElectronic medical recordsHospice transitionUnplanned hospitalizationDischarge dispositionHospice referralInpatient managementLate referralCancer HospitalInterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma
Orlow I, Sadeghi K, Edmiston S, Kenney J, Lezcano C, Wilmott J, Cust A, Scolyer R, Mann G, Lee T, Burke H, Jakrot V, Shang P, Ferguson P, Boyce T, Ko J, Ngo P, Funchain P, Rees J, O’Connell K, Hao H, Parrish E, Conway K, Googe P, Ollila D, Moschos S, Hernando E, Hanniford D, Argibay D, Amos C, Lee J, Osman I, Luo L, Kuan P, Aurora A, Rothberg BE, Bosenberg M, Gerstenblith M, Thompson C, Bogner P, Gorlov I, Holmen S, Brunsgaard E, Saenger Y, Shen R, Seshan V, Nagore E, Ernstoff M, Busam K, Begg C, Thomas N, Berwick M, Consortium O. InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma. PLOS ONE 2023, 18: e0269324. PMID: 37011054, PMCID: PMC10069769, DOI: 10.1371/journal.pone.0269324.Peer-Reviewed Original ResearchConceptsEarly-stage melanomaPrimary melanomaMemorial Sloan-Kettering Cancer CenterDisease-specific survivalPredictors of survivalMulti-institutional settingSomatic mutationsPre-established protocolMiRNA expressionScreening failureMulticenter studyCancer CenterDownstream testingLimited tumor tissueNucleic acid qualityClinical databaseMulticenter researchTumor tissueMelanomaTumor samplesFFPE tumorsArchival tissueFFPE tissue blocksTissue blocksSuccess rateOutcomes on an inpatient oncology service after the introduction of hospitalist comanagement
Morris J, Rothberg BE, Prsic E, Parker N, Weber U, Gombos E, Kottarathara M, Billingsley K, Adelson K. Outcomes on an inpatient oncology service after the introduction of hospitalist comanagement. Journal Of Hospital Medicine 2023, 18: 391-397. PMID: 36891947, DOI: 10.1002/jhm.13071.Peer-Reviewed Original ResearchConceptsLength of stayInpatient oncology serviceSmilow Cancer HospitalSeverity of illnessOncology servicesOncologists' experiencesReadmission ratesEarly dischargeHospitalist comanagementAverage LOSTime of dischargeMean discharge timeEarly discharge ratesImpact of hospitalistsRace/ethnicityDischarge dispositionMultiple admissionsCancer HospitalMAIN OUTCOMEStudy durationPatient volumeCancer typesStudy periodHospitalistsOutcomes
2022
Oncologic emergencies and urgencies: A comprehensive review
Rothberg BE, Quest T, Yeung S, Pelosof L, Gerber D, Seltzer J, Bischof J, Thomas C, Akhter N, Mamtani M, Stutman R, Baugh C, Anantharaman V, Pettit N, Klotz A, Gibbs M, Kyriacou D. Oncologic emergencies and urgencies: A comprehensive review. CA A Cancer Journal For Clinicians 2022, 72: 570-593. PMID: 35653456, DOI: 10.3322/caac.21727.Peer-Reviewed Original ResearchConceptsEmergency departmentChimeric antigen receptor T cellsMalignant spinal cord compressionImmune checkpoint inhibitorsTumor lysis syndromeAntidiuretic hormone secretionSpinal cord compressionChemotherapy-induced mucositisMechanical bowel obstructionCheckpoint inhibitorsFebrile neutropeniaMalignant effusionsSystemic treatmentUrgent care centersAcute decompensationCord compressionT cellsOncologic emergencyVenous thromboembolismBowel obstructionPainful crisesPoint-of-care referencesActive therapyHormone secretionOutpatient oncologists
2021
Impact of a Dedicated Cancer Urgent Care Center on Acute Care Utilization
Rothberg BE, Canavan ME, Mun S, Sedghi T, Carafeno T, Raucci M, Dest V, Sinanis N, Gross CP, Adelson KB. Impact of a Dedicated Cancer Urgent Care Center on Acute Care Utilization. JCO Oncology Practice 2021, 18: e129-e136. PMID: 34383579, DOI: 10.1200/op.21.00183.Peer-Reviewed Original ResearchConceptsUrgent care centersCare centerHospitalization ratesLarge tertiary academic centerAcute care useAcute care utilizationEmergency department presentationsTertiary academic centerEmergency room utilizationCancer care costsPeriod 1 yearProvider visitsActive therapyHospital admissionPrimary outcomeCare utilizationOncology patientsAcute careCare useClinic capacityPatient awarenessPhysician comfortClinical pathwayPatientsAcademic centers
2014
Red meat and fruit intake is prognostic among patients with localized cutaneous melanomas more than 1mm thick
Rothberg BE, Bulloch K, Fine J, Barnhill R, Berwick M. Red meat and fruit intake is prognostic among patients with localized cutaneous melanomas more than 1mm thick. Cancer Epidemiology 2014, 38: 599-607. PMID: 25194935, PMCID: PMC4229370, DOI: 10.1016/j.canep.2014.08.005.Peer-Reviewed Original ResearchConceptsMelanoma-specific survivalLocalized cutaneous melanomaFruit consumptionPost-diagnostic measuresDaily fruit consumptionModifiable lifestyle behaviorsRed meatBreslow thicknessCutaneous melanomaAssociated with melanoma-specific survivalRed meat consumptionAssociated with worse outcomesSurvivorship periodLifestyle behaviorsCancer survivorsPhysical activityTobacco cessationFruit intakeNon-therapeutic interventionsTime of diagnosisCox proportional hazardsHigh fish consumptionDietary choicesIndex melanomaIndependent associations
2013
Marginal and Joint Distributions of S100, HMB-45, and Melan-A Across a Large Series of Cutaneous Melanomas
Viray H, Bradley WR, Schalper KA, Rimm DL, Rothberg BE. Marginal and Joint Distributions of S100, HMB-45, and Melan-A Across a Large Series of Cutaneous Melanomas. Archives Of Pathology & Laboratory Medicine 2013, 137: 1063-73. PMID: 23899062, PMCID: PMC3963468, DOI: 10.5858/arpa.2012-0284-oa.Peer-Reviewed Original ResearchConceptsHMB-45Primary tumorCutaneous melanomaLarge seriesMelanoma-specific survivalMelanoma primary tumorsGroup of antigensLarge tissue microarrayClinicopathologic covariatesClinicopathologic criteriaPrognostic relevanceHistopathologic profileClinicopathologic correlatesAntigen expressionClinicopathologic parametersMelanoma markersTissue microarrayPositive expressionSurvival analysisMelanomaMelanS100Melanoma cellsBivariate associationsSignificant differences
2010
Gestational weight gain and subsequent postpartum weight loss among young, low-income, ethnic minority women
Rothberg BE, Magriples U, Kershaw TS, Rising SS, Ickovics JR. Gestational weight gain and subsequent postpartum weight loss among young, low-income, ethnic minority women. American Journal Of Obstetrics And Gynecology 2010, 204: 52.e1-52.e11. PMID: 20974459, PMCID: PMC3011029, DOI: 10.1016/j.ajog.2010.08.028.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBlack or African AmericanConnecticutFemaleGeorgiaGuidelines as TopicHispanic or LatinoHumansHypertension, Pregnancy-InducedNational Academies of Science, Engineering, and Medicine, U.S., Health and Medicine DivisionObesityOverweightPostpartum PeriodPovertyPregnancyPregnancy Trimester, SecondPregnancy Trimester, ThirdReference ValuesSmokingUnited StatesWeight GainWeight LossWhite PeopleYoung AdultConceptsPostpartum weight lossWeight change trajectoriesGestational weight gainWeight gainWeight lossEthnic minority womenExcessive pregnancy weight gainLow-income ethnic minority womenLongitudinal mixed modelingPregnancy weight gainPregnancy-induced hypertensionMedical record reviewOverweight/obeseBody mass indexWeight management interventionsMinority womenInstitute of MedicineSingleton infantsGestational weightMass indexMedicine guidelinesRecord reviewThird trimesterPrenatal careClinical recommendationsBiomarkers: The Useful and the Not So Useful—An Assessment of Molecular Prognostic Markers for Cutaneous Melanoma
Rothberg BE, Rimm DL. Biomarkers: The Useful and the Not So Useful—An Assessment of Molecular Prognostic Markers for Cutaneous Melanoma. Journal Of Investigative Dermatology 2010, 130: 1971-1987. PMID: 20555347, PMCID: PMC3180927, DOI: 10.1038/jid.2010.149.Peer-Reviewed Original Research
2009
Melanoma Prognostic Model Using Tissue Microarrays and Genetic Algorithms
Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, Bradley WR, Ariyan S, Kluger HM, Rimm DL. Melanoma Prognostic Model Using Tissue Microarrays and Genetic Algorithms. Journal Of Clinical Oncology 2009, 27: 5772-5780. PMID: 19884546, PMCID: PMC2792999, DOI: 10.1200/jco.2009.22.8239.Peer-Reviewed Original ResearchConceptsHigh-risk groupTissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis
Rothberg BE, Bracken MB, Rimm DL. Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis. Journal Of The National Cancer Institute 2009, 101: 452-474. PMID: 19318635, PMCID: PMC2720709, DOI: 10.1093/jnci/djp038.Peer-Reviewed Original ResearchConceptsCohort studyCutaneous melanomaMelanoma cell adhesion moleculeSystematic reviewEarly-stage cutaneous melanomaPotential prognostic valueMatrix metalloproteinase-2Cell nuclear antigenREMARK criteriaAdjuvant therapyMultivariable analysisREMARK guidelinesRisk stratificationPrognostic valueSurvival outcomesIncomplete adherenceMelanoma outcomesClinical managementImmunohistochemical expressionCell adhesion moleculeInclusion criteriaKi-67Tissue biomarkersClinical practiceMetalloproteinase-2
2008
Prognostic Significance of Cadherin-Based Adhesion Molecules in Cutaneous Malignant Melanoma
Kreizenbeck GM, Berger AJ, Subtil A, Rimm DL, Rothberg BE. Prognostic Significance of Cadherin-Based Adhesion Molecules in Cutaneous Malignant Melanoma. Cancer Epidemiology Biomarkers & Prevention 2008, 17: 949-958. PMID: 18398036, PMCID: PMC3312613, DOI: 10.1158/1055-9965.epi-07-2729.Peer-Reviewed Original Research
2006
E-cadherin Immunohistochemical Expression as a Prognostic Factor in Infiltrating Ductal Carcinoma of the Breast: a Systematic Review and Meta-Analysis
Gould Rothberg BE, Bracken MB. E-cadherin Immunohistochemical Expression as a Prognostic Factor in Infiltrating Ductal Carcinoma of the Breast: a Systematic Review and Meta-Analysis. Breast Cancer Research And Treatment 2006, 100: 139-148. PMID: 16791476, DOI: 10.1007/s10549-006-9248-2.Peer-Reviewed Original ResearchConceptsDuctal breast carcinomaBreast cancer-specific mortalityCancer-specific mortalityE-cadherin expressionCause mortalityBreast carcinomaCohort studyPrognostic markerImmunohistochemical expressionSystematic reviewSubstantial inter-study heterogeneityIndependent negative prognostic indicatorRetrospective cohort studyPrimary study outcomeSummary hazard ratioNegative prognostic indicatorInter-study heterogeneityRandom-effects modelClinical data collectionAbsent E-cadherin expressionNon-significant associationCadherin immunohistochemical expressionHazard ratioPrognostic factorsDuctal carcinoma
2003
Re: Hemorrhagic angiomyolipoma and tuberous sclerosis complex: a case report. Recognizing the needs of a growing population of adults with tuberous sclerosis complex.
Rothberg B. Re: Hemorrhagic angiomyolipoma and tuberous sclerosis complex: a case report. Recognizing the needs of a growing population of adults with tuberous sclerosis complex. Connecticut Medicine 2003, 67: 313-4. PMID: 12802849.Peer-Reviewed Original Research